Data on Cystic Fibrosis Reported by Researchers at University of California San Francisco (UCSF) [Selective Isoxazolopyrimidine Pat1 (Slc26a6) Inhibitors for Therapy of Intestinal Disorders].

Předmět:
Zdroj: Gastroenterology Week; 11/6/2023, p734-734, 1p
Abstrakt: Keywords: San Francisco; State:California; United States; North and Central America; Cystic Fibrosis; Drugs and Therapies; Gastroenterology; Health and Medicine; Lung Diseases and Conditions; Pharmaceuticals; Therapy EN San Francisco State:California United States North and Central America Cystic Fibrosis Drugs and Therapies Gastroenterology Health and Medicine Lung Diseases and Conditions Pharmaceuticals Therapy 734 734 1 11/06/23 20231106 NES 231106 2023 NOV 10 (NewsRx) -- By a News Reporter-Staff News Editor at Gastroenterology Week -- Research findings on Lung Diseases and Conditions - Cystic Fibrosis are discussed in a new report. Since CFTR modulators have minimal effects on gastrointestinal symptoms, there is an unmet need for novel treatments for CF-associated gastrointestinal disorders.". [Extracted from the article]
Databáze: Complementary Index